Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib | British Journal of Cancer
Kaplan-Meier analysis of overall survival by first targeted therapy | Download Scientific Diagram
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
Frontiers | Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
Frontiers | Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
322-Renal cell metastatic sUNITinib | eviQ
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma | Anticancer Research
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response ...
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib - The ASCO Post
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma | British Journal of Cancer
Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram
Overall survival for first-line IO combination therapies. CI =... | Download Scientific Diagram
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma | BMC Cancer | Full Text
Sunitinib - Wikipedia
Kaplan-Meier curves showing PFS in patients with sunitinib adverse... | Download Scientific Diagram
Survival distributions for progression-free (PFS) and overall survival... | Download Scientific Diagram
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. | Semantic Scholar
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
